Defence Therapeutics Inc.
DTC
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 90.60% | 72.84% | 23.44% | 0.83% | -317.55% |
| Total Depreciation and Amortization | -- | 36.84% | 5,816.67% | 8,250.00% | -100.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -96.90% | 82.80% | 10,000.00% | -44.52% | 2,875.86% |
| Change in Net Operating Assets | -- | -26.49% | 244.87% | 142.35% | 100.00% |
| Cash from Operations | -- | 106.05% | 75.69% | 47.83% | 100.00% |
| Capital Expenditure | -- | -- | 435.14% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | 435.14% | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -89.12% | -225.81% | -25.81% | -- |
| Issuance of Common Stock | -- | -- | -99.31% | -69.46% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | 43.13% | -- |
| Cash from Financing | -- | 13.76% | -97.29% | -70.77% | -100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | 105.09% | -430.43% | -93.96% | -100.00% |